139 related articles for article (PubMed ID: 31099002)
1. Targeting Cancer with Peptide RNAi Nanoplexes.
Mixson AJ; Leng Q; Chou ST; Woodle MC
Methods Mol Biol; 2019; 1974():161-180. PubMed ID: 31099002
[TBL] [Abstract][Full Text] [Related]
2. Selective modification of HK peptides enhances siRNA silencing of tumor targets in vivo.
Chou ST; Leng Q; Scaria P; Woodle M; Mixson AJ
Cancer Gene Ther; 2011 Oct; 18(10):707-16. PubMed ID: 21818135
[TBL] [Abstract][Full Text] [Related]
3. Dual antitumoral potency of EG5 siRNA nanoplexes armed with cytotoxic bifunctional glutamyl-methotrexate targeting ligand.
Lee DJ; Kessel E; Edinger D; He D; Klein PM; Voith von Voithenberg L; Lamb DC; Lächelt U; Lehto T; Wagner E
Biomaterials; 2016 Jan; 77():98-110. PubMed ID: 26584350
[TBL] [Abstract][Full Text] [Related]
4. Surface-modified HK:siRNA nanoplexes with enhanced pharmacokinetics and tumor growth inhibition.
Chou ST; Leng Q; Scaria P; Kahn JD; Tricoli LJ; Woodle M; Mixson AJ
Biomacromolecules; 2013 Mar; 14(3):752-60. PubMed ID: 23360232
[TBL] [Abstract][Full Text] [Related]
5. Histidine-lysine peptides as carriers of nucleic acids.
Leng Q; Goldgeier L; Zhu J; Cambell P; Ambulos N; Mixson AJ
Drug News Perspect; 2007 Mar; 20(2):77-86. PubMed ID: 17440630
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticulate RNA delivery systems in cancer.
Sharma A; Jha NK; Dahiya K; Singh VK; Chaurasiya K; Jha AN; Jha SK; Mishra PC; Dholpuria S; Astya R; Nand P; Kumar A; Ruokolainen J; Kesari KK
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1271. PubMed ID: 32729987
[TBL] [Abstract][Full Text] [Related]
7. Regulating intracellular fate of siRNA by endoplasmic reticulum membrane-decorated hybrid nanoplexes.
Qiu C; Han HH; Sun J; Zhang HT; Wei W; Cui SH; Chen X; Wang JC; Zhang Q
Nat Commun; 2019 Jun; 10(1):2702. PubMed ID: 31221991
[TBL] [Abstract][Full Text] [Related]
8. The development of ternary nanoplexes for efficient small interfering RNA delivery.
Şalva E; Turan SÖ; Akbuğa J
Biol Pharm Bull; 2013; 36(12):1907-14. PubMed ID: 24432377
[TBL] [Abstract][Full Text] [Related]
9. In vivo application of RNA interference: from functional genomics to therapeutics.
Lu PY; Xie F; Woodle MC
Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
[TBL] [Abstract][Full Text] [Related]
10. Delivery of mRNA with Histidine-Lysine Peptides.
Leng Q; He J; Anand A; Mixson AJ
Methods Mol Biol; 2024; 2822():367-386. PubMed ID: 38907929
[TBL] [Abstract][Full Text] [Related]
11. A Dual Targeting Dendrimer-Mediated siRNA Delivery System for Effective Gene Silencing in Cancer Therapy.
Dong Y; Yu T; Ding L; Laurini E; Huang Y; Zhang M; Weng Y; Lin S; Chen P; Marson D; Jiang Y; Giorgio S; Pricl S; Liu X; Rocchi P; Peng L
J Am Chem Soc; 2018 Nov; 140(47):16264-16274. PubMed ID: 30346764
[TBL] [Abstract][Full Text] [Related]
12. The neuropilin-1 receptor mediates enhanced tumor delivery of H2K polyplexes.
Leng Q; Mixson AJ
J Gene Med; 2016 Jul; 18(7):134-44. PubMed ID: 27257039
[TBL] [Abstract][Full Text] [Related]
13. The role of disulfide-bridge on the activities of H-shape gemini-like cationic lipid based siRNA delivery.
Ma XF; Sun J; Qiu C; Wu YF; Zheng Y; Yu MZ; Pei XW; Wei L; Niu YJ; Pang WH; Yang ZJ; Wang JC; Zhang Q
J Control Release; 2016 Aug; 235():99-111. PubMed ID: 27242198
[TBL] [Abstract][Full Text] [Related]
14. Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells.
Palanca-Wessels MC; Booth GC; Convertine AJ; Lundy BB; Berguig GY; Press MF; Stayton PS; Press OW
Oncotarget; 2016 Feb; 7(8):9561-75. PubMed ID: 26840082
[TBL] [Abstract][Full Text] [Related]
15. Tumor Selective Silencing Using an RNAi-Conjugated Polymeric Nanopharmaceutical.
Svenson S; Case RI; Cole RO; Hwang J; Kabir SR; Lazarus D; Lim Soo P; Ng PS; Peters C; Shum P; Sweryda-Krawiec B; Tripathi S; van der Poll D; Eliasof S
Mol Pharm; 2016 Mar; 13(3):737-47. PubMed ID: 26835715
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and evaluation of VEGF-siRNA/CRS as a novel vector for gene delivery.
Zhao W; Zhang Y; Jiang X; Cui C
Drug Des Devel Ther; 2016; 10():3851-3865. PubMed ID: 27920500
[TBL] [Abstract][Full Text] [Related]
17. T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting.
Kuang Y; An S; Guo Y; Huang S; Shao K; Liu Y; Li J; Ma H; Jiang C
Int J Pharm; 2013 Sep; 454(1):11-20. PubMed ID: 23867728
[TBL] [Abstract][Full Text] [Related]
18. Biodegradable polymer-mediated sh/siRNA delivery for cancer studies.
Jere DJ; Cho CS
Methods Mol Biol; 2010; 623():243-69. PubMed ID: 20217556
[TBL] [Abstract][Full Text] [Related]
19. A Method for Targeted Nonviral siRNA Delivery in Cancer and Inflammatory Diseases.
Kandil R; Xie Y; Mehta A; Merkel O
Methods Mol Biol; 2020; 2059():155-166. PubMed ID: 31435920
[TBL] [Abstract][Full Text] [Related]
20. Assembling Mn:ZnSe quantum dots-siRNA nanoplexes for gene silencing in tumor cells.
Wang Y; Yang C; Hu R; Toh HT; Liu X; Lin G; Yin F; Yoon HS; Yong KT
Biomater Sci; 2015 Jan; 3(1):192-202. PubMed ID: 26214202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
